Price Disclosure Reductions for 2016 April Cycle

This summary of 1 April 2016 price disclosure reductions for the 2016 April Cycle only includes medicines taking a price disclosure reduction. The price disclosure legal determination mentioned below includes brands where there will not be a price disclosure reduction (see Schedule 2 of the determination).

The price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 1960 (the Regulations) in place as at September 2015.

The outcomes below show percentage (%) price differences and ex-manufacturer level prices. They do not include fees and mark-ups.

2015 Price Disclosure Changes

The 2016 April Cycle is the first price disclosure cycle that incorporates the ‘Flow-on Reductions for F2 Combination Items’ and the ‘No Reduction Items – Low Volume / Low Discount’ measures announced under the 2015 Access and Sustainability package of changes to the Pharmaceutical Benefits Scheme (PBS).

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should understand that:

  • if your brand of F2 combination item received a direct price disclosure reduction, this reduction may not take effect on 1 April 2016 if the price of a component ingredient will be reduced on 1 April 2016, and flowing this price on to the combination item will result in a lower price than that of the direct reduction; or
  • if your brand of F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs. Letters will set out the new prices for F2 combination items and seek PB11a forms. F2 combination item pricing will require attention by affected companies during January 2016. This aligns with the usual timeline for combination flow-on pricing for April reduction days.

No Reduction Items – Low Volume / Low Discount

This measure allows for no price disclosure reduction for certain pharmaceutical items with low volume and low discounting, even where other items with the same drug and manner of administration (MoA) will take a reduction on 1 April 2016.

The 2016 April Cycle is the first price disclosure cycle that incorporates the ‘Low Volume / Low Discount’ measure.

Further information regarding these changes can be found on the 2015 Price Disclosure Changes - Fact Sheet.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with no reduction, are in the legal determination on the ComLaw website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2015 PBS approved ex-manufacturer price and the weighted average disclosed price for the 2016 April Cycle was below 10%. Any new brands of an existing pharmaceutical item with a determination in Schedule 1 that listed after 30 September 2015 will also take the reduction on 1 April 2016 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on Wednesday, 23 December 2015. 

Indicative prices for 1 April 2016 (including price to pharmacy, Dispensed Price for Maximum Quantity and price premiums) will be published by late January 2016. Subscribe to PBS News to receive notice when they become available.

Final prices for 1 April 2016 (including all price to pharmacy, Dispensed Price for Maximum Quantity/Amount and price premiums) will be available from early March 2016.

2016 April Cycle Outcomes Summary
Legal Instrument Drug
(drugs marked with an * have a pharmaceutical item/s that met the ‘Low Volume Low Discount criteria’ therefore those items will not take a reduction)		 Legal Instrument MoA Legal Instrument Form Average
AEMP
($)		 WAPD
(%)
across a
drug/MoA		 WADP -
potential
April '16
PBS Price (AEMP)
($)
per
pharmaceutical
item		 October '15
AEMP
($)		 Percentage difference between October '15 and April '16  PBS prices (AEMP)
(%)
per
pharmaceutical
item
[Average AEMP minus WAPD = WADP] [Difference between October AEMP & WADP =
% Difference]
alendronic acid with colecalciferol and calcium oral pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate) 31.85 13.67% 27.50 31.85 13.66%
amisulpride oral tablet 100 mg 10.07 14.96% 8.56 10.07 15.00%
amisulpride oral tablet 200 mg 43.35 14.96% 36.86 43.35 14.97%
amisulpride oral tablet 400 mg 78.61 14.96% 66.85 78.61 14.96%
amlodipine oral tablet 10 mg (as besylate) 2.12 16.96% 1.76 2.12 16.98%
amlodipine oral tablet 5 mg (as besylate) 1.21 16.96% 1.00 1.21 17.36%
anastrozole oral tablet 1 mg 66.65 26.24% 49.16 55.73 11.79%
atorvastatin oral tablet 10 mg (as calcium) 3.76 37.09% 2.37 2.78 14.75%
atorvastatin oral tablet 20 mg (as calcium) 5.55 37.09% 3.49 4.10 14.88%
atorvastatin oral tablet 40 mg (as calcium) 7.82 37.09% 4.92 5.77 14.73%
atorvastatin oral tablet 80 mg (as calcium) 11.18 37.09% 7.03 8.25 14.79%
azathioprine oral tablet 25 mg 15.74 10.02% 14.16 15.74 10.04%
azathioprine oral tablet 50 mg 26.79 10.02% 24.11 26.79 10.00%
azithromycin oral tablet 500 mg (as dihydrate) 5.25 13.51% 4.54 5.25 13.52%
azithromycin oral tablet 600 mg (as dihydrate) 64.03 13.51% 55.38 64.03 13.51%
bicalutamide oral tablet 50 mg 81.83 14.07% 70.32 81.83 14.07%
bisoprolol oral tablet containing bisoprolol fumarate 10 mg 21.89 24.04% 16.63 18.68 10.97%
bisoprolol oral tablet containing bisoprolol fumarate 2.5 mg 14.01 24.04% 10.64 11.96 11.04%
bisoprolol oral tablet containing bisoprolol fumarate 5 mg 17.51 24.04% 13.30 14.94 10.98%
candesartan oral tablet containing candesartan cilexetil 16 mg 9.88 33.43% 6.58 7.85 16.18%
candesartan oral tablet containing candesartan cilexetil 32 mg 11.94 33.43% 7.95 9.49 16.23%
candesartan oral tablet containing candesartan cilexetil 4 mg 1.11 33.43% 0.74 0.88 15.91%
candesartan oral tablet containing candesartan cilexetil 8 mg 3.30 33.43% 2.20 2.62 16.03%
capecitabine oral tablet 150 mg 83.46 63.22% 30.70 40.04 23.33%
capecitabine oral tablet 500 mg 517.39 63.22% 190.30 248.19 23.32%
carvedilol oral tablet 12.5 mg 15.18 13.60% 13.12 15.18 13.57%
carvedilol oral tablet 25 mg 18.98 13.60% 16.40 18.98 13.59%
carvedilol oral tablet 3.125 mg 2.57 13.60% 2.22 2.57 13.62%
carvedilol oral tablet 6.25 mg 12.14 13.60% 10.49 12.14 13.59%
celecoxib oral capsule 100 mg 17.59 38.62% 10.80 17.59 38.60%
celecoxib oral capsule 200 mg 17.59 38.62% 10.80 17.59 38.60%
clindamycin oral capsule 150 mg (as hydrochloride) 9.06 13.18% 7.87 9.06 13.13%
clopidogrel oral tablet 75 mg 7.23 23.35% 5.54 7.23 23.37%
clopidogrel oral tablet 75 mg (as besilate) 7.23 23.35% 5.54 7.23 23.37%
clopidogrel oral tablet 75 mg (as hydrogen sulfate) 7.23 23.35% 5.54 7.23 23.37%
clopidogrel with aspirin oral tablet 75 mg (as hydrogen sulfate)-100 mg 27.33 23.93% 20.79 27.33 23.93%
desvenlafaxine oral tablet (extended release) 100 mg (as succinate) 29.29 22.66% 22.65 29.29 22.67%
desvenlafaxine oral tablet (extended release) 50 mg (as succinate) 23.85 22.66% 18.45 23.85 22.64%
desvenlafaxine oral tablet (modified release) 100 mg 29.29 22.66% 22.65 29.29 22.67%
desvenlafaxine oral tablet (modified release) 100 mg (as benzoate) 29.29 22.66% 22.65 29.29 22.67%
desvenlafaxine oral tablet (modified release) 50 mg 23.85 22.66% 18.45 23.85 22.64%
desvenlafaxine oral tablet (modified release) 50 mg (as benzoate) 23.85 22.66% 18.45 23.85 22.64%
doxorubicin injection/intravesical solution for i.v. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 ml single dose vial 2.20 20.87% 1.74 2.20 20.91%
doxorubicin injection/intravesical solution for i.v. injection or intravesical administration containing doxorubicin hydrochloride 100 mg in 50 ml single dose vial 18.59 20.87% 14.71 18.59 20.87%
doxorubicin injection/intravesical solution for i.v. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 ml single dose vial 37.17 20.87% 29.41 37.17 20.88%
doxorubicin injection/intravesical solution for i.v. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 ml single dose vial 9.30 20.87% 7.36 9.30 20.86%
duloxetine oral capsule 30 mg (as hydrochloride) 9.66 37.10% 6.08 7.47 18.61%
duloxetine oral capsule 60 mg (as hydrochloride) 13.79 37.10% 8.67 10.67 18.74%
escitalopram oral tablet 10 mg (as oxalate) 3.40 19.72% 2.73 3.40 19.71%
escitalopram oral tablet 20 mg (as oxalate) 3.43 19.72% 2.75 3.43 19.83%
esomeprazole oral capsule (enteric) 20 mg (as magnesium) 15.05 16.40% 12.58 15.05 16.41%
esomeprazole oral capsule (enteric) 40 mg (as magnesium) 25.52 16.40% 21.33 25.52 16.42%
esomeprazole oral tablet (enteric coated) 20 mg (as magnesium trihydrate) 15.05 16.40% 12.58 15.05 16.41%
esomeprazole oral tablet (enteric coated) 40 mg (as magnesium trihydrate) 25.52 16.40% 21.33 25.52 16.42%
exemestane oral tablet 25 mg 84.64 15.32% 71.67 84.64 15.32%
famciclovir oral tablet 125 mg 42.50 26.18% 31.37 36.22 13.39%
famciclovir oral tablet 250 mg 42.50 26.18% 31.37 36.22 13.39%
famciclovir oral tablet 500 mg 63.75 26.18% 47.06 54.33 13.38%
fentanyl transdermal transdermal patch 1.28 mg 12.73 16.08% 10.68 12.73 16.10%
fentanyl transdermal transdermal patch 10.20 mg 50.59 16.08% 42.46 50.59 16.07%
fentanyl transdermal transdermal patch 12.375 mg 40.77 16.08% 34.21 40.77 16.09%
fentanyl transdermal transdermal patch 12.6 mg 40.77 16.08% 34.21 40.77 16.09%
fentanyl transdermal transdermal patch 16.5 mg 50.59 16.08% 42.46 50.59 16.07%
fentanyl transdermal transdermal patch 16.8 mg 50.59 16.08% 42.46 50.59 16.07%
fentanyl transdermal transdermal patch 2.063 mg 12.73 16.08% 10.68 12.73 16.10%
fentanyl transdermal transdermal patch 2.1 mg 12.73 16.08% 10.68 12.73 16.10%
fentanyl transdermal transdermal patch 2.55 mg 16.19 16.08% 13.59 16.19 16.06%
fentanyl transdermal transdermal patch 4.125 mg 16.19 16.08% 13.59 16.19 16.06%
fentanyl transdermal transdermal patch 4.2 mg 16.19 16.08% 13.59 16.19 16.06%
fentanyl transdermal transdermal patch 5.10 mg 29.75 16.08% 24.97 29.75 16.07%
fentanyl transdermal transdermal patch 7.65 mg 40.77 16.08% 34.21 40.77 16.09%
fentanyl transdermal transdermal patch 8.25 mg 29.75 16.08% 24.97 29.75 16.07%
fentanyl transdermal transdermal patch 8.4 mg 29.75 16.08% 24.97 29.75 16.07%
fluoxetine oral capsule 20 mg (as hydrochloride) 4.52 12.02% 3.98 4.52 11.95%
fluoxetine oral tablet, dispersible, 20 mg (as hydrochloride) 4.52 12.02% 3.98 4.52 11.95%
folinic acid injection injection containing calcium folinate equivalent to 1000 mg folinic acid in 100 ml 40.47 11.09% 35.98 40.47 11.09%
folinic acid injection injection containing calcium folinate equivalent to 300 mg folinic acid in 30 ml 11.84 11.09% 10.53 11.84 11.06%
folinic acid injection injection containing calcium folinate equivalent to 50 mg folinic acid in 5 ml 4.38 11.09% 3.89 4.38 11.19%
gabapentin oral capsule 100 mg 5.00 13.90% 4.31 5.00 13.80%
gabapentin oral capsule 300 mg 16.71 13.90% 14.39 16.71 13.88%
gabapentin oral capsule 400 mg 22.79 13.90% 19.62 22.79 13.91%
gabapentin oral tablet 600 mg 36.18 13.90% 31.15 36.18 13.90%
gabapentin oral tablet 800 mg 48.23 13.90% 41.53 48.23 13.89%
irbesartan oral tablet 150 mg 4.14 32.47% 2.80 3.25 13.85%
irbesartan oral tablet 300 mg 8.27 32.47% 5.58 6.50 14.15%
irbesartan oral tablet 75 mg 2.90 32.47% 1.96 2.28 14.04%
iron polymaltose complex injection injection 100 mg (iron) in 2 ml 20.31 42.28% 11.72 16.64 29.57%
labetalol oral tablet containing labetalol hydrochloride 100 mg 7.98 2.32% 7.79 9.61 18.94%
labetalol oral tablet containing labetalol hydrochloride 200 mg 12.61 2.32% 12.32 14.25 13.54%
lamivudine* oral tablet 100 mg 81.22 21.52% 63.74 81.22 21.52%
lamivudine* oral tablet 150 mg 153.34 21.52% 120.34 153.34 21.52%
lamivudine* oral tablet 300 mg 153.34 21.52% 120.34 153.34 21.52%
lamotrigine* oral tablet 100 mg 22.28 20.49% 17.71 22.28 20.51%
lamotrigine* oral tablet 200 mg 37.44 20.49% 29.77 37.44 20.49%
lamotrigine* oral tablet 25 mg 8.02 20.49% 6.38 8.02 20.45%
lamotrigine* oral tablet 50 mg 13.38 20.49% 10.64 13.38 20.48%
lansoprazole oral capsule 15 mg 5.81 15.28% 4.92 5.81 15.32%
lansoprazole oral capsule 30 mg 9.70 15.28% 8.22 9.70 15.26%
lansoprazole oral tablet 15 mg (orally disintegrating) 5.40 15.28% 4.57 5.40 15.37%
lansoprazole oral tablet 30 mg (orally disintegrating) 9.70 15.28% 8.22 9.70 15.26%
latanoprost application to the eye eye drops 50 micrograms per ml, 2.5 ml 13.99 17.33% 11.57 13.99 17.30%
leflunomide oral tablet 10 mg 35.04 13.29% 30.38 35.04 13.30%
leflunomide oral tablet 20 mg 53.34 13.29% 46.25 53.34 13.29%
letrozole oral tablet 2.5 mg 62.29 31.94% 42.39 47.88 11.47%
levetiracetam* oral tablet 1 g 58.57 17.33% 48.42 58.57 17.33%
levetiracetam* oral tablet 250 mg 21.09 17.33% 17.44 21.09 17.31%
levetiracetam* oral tablet 500 mg 35.15 17.33% 29.06 35.15 17.33%
lisinopril oral tablet 10 mg 3.92 10.73% 3.50 3.92 10.71%
lisinopril oral tablet 20 mg 4.94 10.73% 4.41 4.94 10.73%
lisinopril oral tablet 5 mg 2.62 10.73% 2.34 2.62 10.69%
meloxicam oral capsule 15 mg 5.33 11.57% 4.71 5.33 11.63%
meloxicam oral capsule 7.5 mg 3.65 11.57% 3.23 3.65 11.51%
meloxicam oral tablet 15 mg 5.33 11.57% 4.71 5.33 11.63%
meloxicam oral tablet 7.5 mg 3.65 11.57% 3.23 3.65 11.51%
methylprednisolone* injection powder for injection 1 g (as sodium succinate) 41.31 15.96% 34.72 41.31 15.95%
metoclopramide oral tablet containing metoclopramide hydrochloride 10 mg 1.21 13.30% 1.05 1.21 13.22%
metoprolol succinate oral tablet 190 mg (controlled release) 73.28 13.94% 63.06 73.28 13.95%
metoprolol succinate oral tablet 23.75 mg (controlled release) 9.93 13.94% 8.55 9.93 13.90%
metoprolol succinate oral tablet 47.5 mg (controlled release) 46.91 13.94% 40.37 46.91 13.94%
metoprolol succinate oral tablet 95 mg (controlled release) 58.62 13.94% 50.45 58.62 13.94%
mirtazapine oral tablet 15 mg 3.18 17.75% 2.62 3.18 17.61%
mirtazapine oral tablet 15 mg (orally disintegrating) 5.49 17.75% 4.52 5.49 17.67%
mirtazapine oral tablet 30 mg 4.78 17.75% 3.93 4.78 17.78%
mirtazapine oral tablet 30 mg (orally disintegrating) 7.32 17.75% 6.02 7.32 17.76%
mirtazapine oral tablet 45 mg 7.96 17.75% 6.55 7.96 17.71%
mirtazapine oral tablet 45 mg (orally disintegrating) 11.03 17.75% 9.07 11.03 17.77%
mitozantrone injection injection 20 mg (as hydrochloride) in 10 ml 61.51 14.19% 52.78 61.51 14.19%
mitozantrone injection injection 25 mg (as hydrochloride) in 12.5 ml 76.85 14.19% 65.94 76.85 14.20%
mometasone application cream containing mometasone furoate 1 mg per g, 15 g 4.52 14.93% 3.85 4.52 14.82%
mometasone application lotion containing mometasone furoate 1 mg per g, 30 ml 7.13 14.93% 6.07 7.13 14.87%
mometasone application ointment containing mometasone furoate 1 mg per g, 15 g 4.52 14.93% 3.85 4.52 14.82%
nevirapine oral tablet 200 mg 198.09 20.67% 157.14 198.09 20.67%
nevirapine oral tablet 400 mg (extended release) 198.09 20.67% 157.14 198.09 20.67%
olanzapine oral tablet 10 mg 33.76 43.29% 19.15 25.21 24.04%
olanzapine oral tablet 10 mg (as benzoate) 33.76 43.29% 19.15 25.21 24.04%
olanzapine oral tablet 10 mg (orally disintegrating) 33.76 43.29% 19.15 25.21 24.04%
olanzapine oral tablet 15 mg (orally disintegrating) 50.63 43.29% 28.71 37.81 24.07%
olanzapine oral tablet 2.5 mg 8.44 43.29% 4.79 6.30 23.97%
olanzapine oral tablet 2.5 mg (as benzoate) 8.44 43.29% 4.79 6.30 23.97%
olanzapine oral tablet 20 mg (orally disintegrating) 67.51 43.29% 38.28 50.42 24.08%
olanzapine oral tablet 5 mg 16.71 43.29% 9.48 12.48 24.04%
olanzapine oral tablet 5 mg (as benzoate) 16.71 43.29% 9.48 12.48 24.04%
olanzapine oral tablet 5 mg (orally disintegrating) 16.71 43.29% 9.48 12.48 24.04%
olanzapine oral tablet 7.5 mg 25.32 43.29% 14.36 18.91 24.06%
olanzapine oral tablet 7.5 mg (as benzoate) 25.32 43.29% 14.36 18.91 24.06%
olanzapine oral wafer 10 mg 33.76 43.29% 19.15 25.21 24.04%
olanzapine oral wafer 15 mg 50.63 43.29% 28.71 37.81 24.07%
olanzapine oral wafer 20 mg 67.51 43.29% 38.28 50.42 24.08%
olanzapine oral wafer 5 mg 16.71 43.29% 9.48 12.48 24.04%
omeprazole* oral capsule 20 mg 5.48 13.51% 4.74 5.48 13.50%
omeprazole* oral tablet 20 mg 5.48 13.51% 4.74 5.48 13.50%
omeprazole* oral tablet 20 mg (as magnesium) 5.48 13.51% 4.74 5.48 13.50%
pamidronic acid injection concentrated injection containing disodium pamidronate 15 mg in 5 ml 17.16 19.51% 13.81 15.39 10.27%
pamidronic acid injection concentrated injection containing disodium pamidronate 30 mg in 10 ml 34.33 19.51% 27.63 30.78 10.23%
pamidronic acid injection concentrated injection containing disodium pamidronate 60 mg in 10 ml 68.65 19.51% 55.26 61.54 10.20%
pamidronic acid injection concentrated injection containing disodium pamidronate 90 mg in 10 ml 102.98 19.51% 82.89 92.32 10.21%
pantoprazole oral tablet (enteric coated) 20 mg (as sodium sesquihydrate) 1.88 15.95% 1.58 1.88 15.96%
pantoprazole oral tablet (enteric coated) 40 mg (as sodium sesquihydrate) 3.87 15.95% 3.25 3.87 16.02%
perindopril oral tablet containing perindopril arginine 10 mg 6.66 12.16% 5.85 6.66 12.16%
perindopril oral tablet containing perindopril arginine 2.5 mg 2.33 12.16% 2.05 2.33 12.02%
perindopril oral tablet containing perindopril arginine 5 mg 4.35 12.16% 3.82 4.35 12.18%
perindopril oral tablet containing perindopril erbumine 2 mg 2.33 12.16% 2.05 2.33 12.02%
perindopril oral tablet containing perindopril erbumine 4 mg 4.35 12.16% 3.82 4.35 12.18%
perindopril oral tablet containing perindopril erbumine 8 mg 6.66 12.16% 5.85 6.66 12.16%
perindopril with indapamide* oral tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg 10.55 12.90% 9.19 10.55 12.89%
perindopril with indapamide* oral tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg 10.55 12.90% 9.19 10.55 12.89%
pioglitazone oral tablet 15 mg (as hydrochloride) 14.64 18.27% 11.97 14.64 18.24%
pioglitazone oral tablet 30 mg (as hydrochloride) 22.52 18.27% 18.41 22.52 18.25%
pioglitazone oral tablet 45 mg (as hydrochloride) 29.28 18.27% 23.93 29.28 18.27%
pravastatin oral tablet containing pravastatin sodium 10 mg 2.00 13.93% 1.72 2.00 14.00%
pravastatin oral tablet containing pravastatin sodium 20 mg 3.17 13.93% 2.73 3.17 13.88%
pravastatin oral tablet containing pravastatin sodium 40 mg 4.93 13.93% 4.24 4.93 14.00%
pravastatin oral tablet containing pravastatin sodium 80 mg 7.58 13.93% 6.52 7.58 13.98%
quetiapine oral tablet (modified release) 150 mg (as fumarate) 45.01 31.91% 30.65 34.85 12.05%
quetiapine oral tablet (modified release) 200 mg (as fumarate) 61.33 31.91% 41.76 47.49 12.07%
quetiapine oral tablet (modified release) 300 mg (as fumarate) 89.99 31.91% 61.27 69.67 12.06%
quetiapine oral tablet (modified release) 400 mg (as fumarate) 122.67 31.91% 83.53 94.97 12.05%
quetiapine oral tablet (modified release) 50 mg (as fumarate) 31.81 31.91% 21.66 24.63 12.06%
quetiapine oral tablet 100 mg (as fumarate) 45.01 31.91% 30.65 34.85 12.05%
quetiapine oral tablet 200 mg (as fumarate) 61.33 31.91% 41.76 47.49 12.07%
quetiapine oral tablet 25 mg (as fumarate) 15.91 31.91% 10.83 12.31 12.02%
quetiapine oral tablet 300 mg (as fumarate) 89.99 31.91% 61.27 69.67 12.06%
rabeprazole oral tablet containing rabeprazole sodium 10 mg (enteric coated) 6.74 26.71% 4.94 5.88 15.99%
rabeprazole oral tablet containing rabeprazole sodium 20 mg (enteric coated) 6.74 26.71% 4.94 5.88 15.99%
raloxifene oral tablet containing raloxifene hydrochloride 60 mg 36.54 14.06% 31.40 36.54 14.07%
ranitidine* oral tablet 150 mg (as hydrochloride) 4.33 11.07% 3.85 4.33 11.09%
ranitidine* oral tablet 300 mg (as hydrochloride) 4.33 11.07% 3.85 4.33 11.09%
riluzole oral tablet 50 mg 321.02 16.29% 268.73 321.02 16.29%
rosuvastatin oral tablet 10 mg (as calcium) 16.11 37.50% 10.07 12.32 18.26%
rosuvastatin oral tablet 20 mg (as calcium) 22.93 37.50% 14.33 17.54 18.30%
rosuvastatin oral tablet 40 mg (as calcium) 32.71 37.50% 20.44 25.01 18.27%
rosuvastatin oral tablet 5 mg (as calcium) 10.97 37.50% 6.86 8.39 18.24%
sertraline oral tablet 100 mg (as hydrochloride) 2.26 17.91% 1.86 2.26 17.70%
sertraline oral tablet 50 mg (as hydrochloride) 2.26 17.91% 1.86 2.26 17.70%
sildenafil oral tablet 20 mg (as citrate) 754.68 31.79% 514.77 574.01 10.32%
telmisartan oral tablet 40 mg 5.27 36.69% 3.34 3.75 10.93%
telmisartan oral tablet 80 mg 15.28 36.69% 9.67 10.86 10.96%
telmisartan with hydrochlorothiazide oral tablet 40 mg-12.5 mg 6.68 33.33% 4.45 5.25 15.24%
telmisartan with hydrochlorothiazide oral tablet 80 mg-12.5 mg 16.69 33.33% 11.13 13.12 15.17%
telmisartan with hydrochlorothiazide oral tablet 80 mg-25 mg 18.10 33.33% 12.07 14.23 15.18%
terbinafine oral tablet 250 mg (as hydrochloride) 25.93 14.70% 22.12 25.93 14.69%
topiramate oral capsule 15 mg 9.41 20.05% 7.52 9.41 20.09%
topiramate oral capsule 25 mg 12.72 20.05% 10.17 12.72 20.05%
topiramate oral capsule 50 mg 21.21 20.05% 16.96 21.21 20.04%
topiramate oral tablet 100 mg 33.40 20.05% 26.70 33.40 20.06%
topiramate oral tablet 200 mg 56.12 20.05% 44.87 56.12 20.05%
topiramate oral tablet 25 mg 12.93 20.05% 10.34 12.93 20.03%
topiramate oral tablet 50 mg 21.24 20.05% 16.98 21.24 20.06%
topotecan injection powder for i.v. infusion 4 mg (as hydrochloride) 64.53 29.75% 45.33 64.53 29.75%
tramadol injection injection containing tramadol hydrochloride 100 mg in 2 ml 4.18 20.88% 3.31 3.70 10.54%
valaciclovir oral tablet 500 mg (as hydrochloride) 12.12 30.73% 8.40 10.64 21.05%
venlafaxine oral capsule (modified release) 150 mg (as hydrochloride) 9.75 31.89% 6.64 7.80 14.87%
venlafaxine oral capsule (modified release) 37.5 mg (as hydrochloride) 4.53 31.89% 3.09 3.62 14.64%
venlafaxine oral capsule (modified release) 75 mg (as hydrochloride) 8.00 31.89% 5.45 6.39 14.71%
zolmitriptan oral tablet 2.5 mg 7.85 10.30% 7.04 7.85 10.32%

Confirmed prices of brands scheduled for a price disclosure reduction

The Confirmed Prices Report outlines the approved ex-manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2016 April cycle can be downloaded below.

Last updated
22 March 2016